Rheumatoid Arthritis Affecting Patents (Class 514/16.6)
-
Patent number: 8338376Abstract: This invention relates to methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. This invention also relates to improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof.Type: GrantFiled: September 15, 2009Date of Patent: December 25, 2012Assignee: Biogen Idec MA Inc.Inventors: Evan Beckman, Graham K. Farrington, Werner Meier, Jeffrey L. Browning
-
Patent number: 8338367Abstract: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.Type: GrantFiled: October 13, 2009Date of Patent: December 25, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Alexander Heim-Riether, Shuang Liang, Sabine Schlyer
-
Patent number: 8329637Abstract: The invention discloses a combined preparation containing IL-10 and rapamycin, able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune responses mediated by T cells.Type: GrantFiled: August 16, 2007Date of Patent: December 11, 2012Inventors: Maria Grazia Roncarolo, Manuela Battaglia
-
Publication number: 20120309686Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.Type: ApplicationFiled: July 9, 2012Publication date: December 6, 2012Applicant: Novozymes Adenium Biotech A/SInventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
-
Publication number: 20120309673Abstract: Compounds of Formula II wherein R1a is H; and R1b is C1-C6alkyl, Carbocyclyl or Het; or R1a and R1b together define a saturated cyclic amine with 3-6 ring atoms; R2a and R2b are independently H, halo, C1-C4alkyl, C1-C4haloalkyl or C1-C4alkoxy, or R2a and R2b together with the carbon atom to which they are attached form a C3-C6cycloalkyl; R3 is a branched C5-C10 alkyl chain, C2-C4haloalkyl or —CH2C3-C7 cycloalkyl; R4? is C1-C6alkyl, C1-C6haloalkyl or oxetany-3-yl. for use in the prophylaxis or treatment of a disorder characterised by inappropriate expression or activation of cathepsin S.Type: ApplicationFiled: December 10, 2010Publication date: December 6, 2012Applicant: Medivir UK LtdInventors: Susana Ayesa, Karolina Ersmark, Urszula Grabowska, Ellen Hewitt, Daniel Jönsson, Pia Kahnberg, Björn Klasson, Peter Lind, Stina Lundgren, Lourdes Odén, Kevin Parkes, Daniel Wiktelius
-
Patent number: 8324164Abstract: Peptides of human heat shock protein of 60 kDa, that constitute epitopes for T cells, as well as their derived peptides, which are modified at the contact sites with the MHC molecule, are useful to induce mechanisms of peripheral tolerance, in particular mechanisms of anergy or mediated by clones of regulatory T cells in patients with Rheumatoid Arthritis. The invention also refers pharmaceutical compositions comprising such peptides for the treatment of Rheumatoid Arthritis.Type: GrantFiled: December 30, 2009Date of Patent: December 4, 2012Assignee: Centro de Ingenieria Genetica Y BiotecnologiaInventors: Maria del Carmen Domínguez Horta, Gabriel Ramón Padrón Palomares, Nelia López Marin, Norailys Lorenzo Perez, Ariana Barberá Betancourt, Ariadna Hernández Garcia, Vivian Morera Cordova, Carelia Cosme Diaz, Nelson J. Merino Garcia, Ariel Vázquez Bonachea, José Suárez Alba
-
Patent number: 8323648Abstract: Methods are provided for identifying agents that modulate intracellular calcium. Also provided are methods of modulating calcium within cells and methods of identifying proteins involved in modulating intracellular calcium.Type: GrantFiled: September 1, 2010Date of Patent: December 4, 2012Assignee: Calcimedica, Inc.Inventors: Jack Roos, Kenneth A. Stauderman, Gonul Velicelebi, Paul J. Digregorio, Kari Lynn Ohlsen
-
Publication number: 20120301397Abstract: The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula Ab-X where the group Ab comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.Type: ApplicationFiled: June 21, 2012Publication date: November 29, 2012Inventors: Philip S. Low, Mary Jo Turk
-
Publication number: 20120302493Abstract: The invention relates to novel cyclic compounds which have the ability to modulate the activity of G protein-coupled receptors. The compounds preferably act as antagonists. In preferred embodiments, the invention provides cyclic peptidic and peptidomimetic antagonists of C5a receptors, which are active against C5a receptors on polymorphonuclear leukocytes and macrophages. The compounds of the invention are both potent and selective, and are useful in the treatment of a variety of inflammatory conditions.Type: ApplicationFiled: February 2, 2012Publication date: November 29, 2012Applicant: Promics PTY LimitedInventors: Stephen Maxwell Taylor, Ian Alexander Shiels, David Fairlie, Darren March, Michael W. Whitehouse
-
Publication number: 20120289452Abstract: A method for treating and/or preventing cell necrosis and diseases associated therewith, comprising the inhibition of one or more elastase enzymes within said cells.Type: ApplicationFiled: June 21, 2011Publication date: November 15, 2012Applicant: Ilana NathanInventors: Ilana NATHAN, Alexandra Lichtenstein
-
Patent number: 8303958Abstract: The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered 0-linked glycosylation pattern. The disclosure also provides methods and pharmaceutical compositions for treating B-cell- and T-cell-mediated disorders.Type: GrantFiled: August 19, 2011Date of Patent: November 6, 2012Assignee: Biogen Idec MA Inc.Inventors: Christine Ambrose, Jeffrey Thompson, Yen-Ming Hsu, Dingyi Wen, Yaping Sun
-
Publication number: 20120277142Abstract: Provided is a modified human tumor necrosis factor receptor-1 polypeptide or a fragment thereof that binds to a tumor necrosis factor in vivo or ex vivo. The modified human tumor necrosis factor receptor-1 polypeptide or fragment exhibits improved ability to bind tumor necrosis factor and resistance to proteases.Type: ApplicationFiled: December 21, 2011Publication date: November 1, 2012Applicant: HANALL BIOPHARMA CO., LTD.Inventors: Sung Wuk Kim, Sung Soo Jun, Seung Kook Park, Song Young Kim, Eun Sun Kim, Jae Kap Jeong, Ha Na Kim, Yeon Jung Song
-
Publication number: 20120276126Abstract: The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.Type: ApplicationFiled: July 11, 2012Publication date: November 1, 2012Applicant: AGENNIX AGInventors: Atul Varadhachary, Rick Barsky, Federica Pericle, Karel Petrak, Yenyun Wang
-
Publication number: 20120270769Abstract: The present invention relates to novel macrocyclic compounds and salts thereof that bind to and/or are inhibitors of serine protease enzymes and methods of using the compounds. The present invention also relates to intermediates of these compounds, pharmaceutical compositions containing these compounds and methods of using the same. These compounds are useful as therapeutics for treatment and prevention of a range of disease indications including hyperproliferative disorders, in particular those characterized by tumor metastasis, inflammatory disorders, skin and tissue disorders, cardiovascular disorders, respiratory disorders and viral infections.Type: ApplicationFiled: October 22, 2010Publication date: October 25, 2012Inventors: Éric Marsault, Olivier Leogane, Axel Mathieu, Sylvie Beaubien, Richard Leduc
-
Patent number: 8287866Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.Type: GrantFiled: November 10, 2010Date of Patent: October 16, 2012Assignee: ZymoGenetics, Inc.Inventors: Wayne R. Kindsvogel, Stavros Topouzis
-
Publication number: 20120258905Abstract: Described herein are compositions, methods, compounds, conjugates, and kits for use in targeted drug delivery using drug delivery conjugates containing hydrophilic spacer linkers for use in treating disease states caused by pathogenic cell populations, such as inflammatory cells.Type: ApplicationFiled: December 22, 2010Publication date: October 11, 2012Applicant: ENDOCYTE, INC.Inventors: Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Yingjuan June Lu
-
Publication number: 20120245091Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: ApplicationFiled: August 24, 2010Publication date: September 27, 2012Applicant: SUPADELIXIR INC.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
-
Publication number: 20120245081Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.Type: ApplicationFiled: August 15, 2011Publication date: September 27, 2012Applicant: Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Ramachandran Murali, Akihiro Hasegawa
-
Patent number: 8273710Abstract: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.Type: GrantFiled: November 30, 2005Date of Patent: September 25, 2012Assignee: Campina Nederland Holding B.V.Inventor: Jan-Willem Pieter Boots
-
Patent number: 8268566Abstract: A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed.Type: GrantFiled: November 11, 2008Date of Patent: September 18, 2012Assignees: Hitachi Chemical Research Center, Inc., Hitachi Chemical Co., Ltd.Inventors: Masato Mitsuhashi, Katsuya Endo, Kazuhiko Obara, Hiroshi Izutsu, Shuji Ohta
-
Patent number: 8263118Abstract: The present invention describes a new bioresorbable filler constituted by hyaluronic acid and/or the derivatives thereof structured with/in phospholipid liposomes, which increase the residence time of the starting polymer in situ. Said fillers described herein are substantially intended to increase the soft tissues in aesthetic surgery and dermocosmetics for the correction of mild to medium defects, but because of their special characteristics they can also be used in other fields of application.Type: GrantFiled: February 15, 2012Date of Patent: September 11, 2012Assignee: Fidia Farmaceutici S.p.A.Inventors: Lanfranco Callegaro, Devis Galesso, Anna Taglienti
-
Publication number: 20120225808Abstract: The present invention relates to a pharmaceutical composition for preventing or treating TRPV1 activity-related or inflammation-related, diseases or conditions, containing a Maillard peptide separated from well-aged traditional soy sauce as an active ingredient. The Maillard peptide according to the present invention functions both as a TRPV1 agonist and a TRPV1 antagonist, and thus functions as a TRPV1 activity modulator. Therefore, the present Maillard peptide can be used as a pharmaceutical composition for preventing or treating TRPV1 activity-related diseases such as pain, neurological diseases, urgent defecation, inflammatory bowel disease, respiratory diseases, urinary incontinence, overactive bladder, neurogenic/allergic/inflammatory skin diseases, skin, eye or mucosal irritation, hyperacusis, tinnitus, vestibular hypersensitivity, heart disease, etc.Type: ApplicationFiled: November 8, 2010Publication date: September 6, 2012Applicants: SNU R&DB FOUNDATION, KOREA FOOD RESEARCH INSTITUTEInventors: Mee-Ra Rhyu, Ah-Young Song, Eun-Young Kim, Seog Bae Oh, YoungJoo Lee, Won Chung Lim
-
Publication number: 20120225820Abstract: Antigenic peptides that bind to MHC Class II molecules with the shared epitope referred to as HLA-DR molecules are disclosed. More specifically, are citrullinated antigenic peptides having an increased affinity for HLA-DR molecules and associated with rheumatoid arthritis. These novel peptides provide the basis for new methods of diagnosis and treatment of rheumatoid arthritis.Type: ApplicationFiled: May 15, 2012Publication date: September 6, 2012Applicant: LONDON HEALTH SCIENCES CENTRE RESEARCH INC.Inventors: Jonathan Hill, Ewa Cairns, David Bell
-
Publication number: 20120214731Abstract: The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to Pseudonocardia and recovering the compound from a culture broth, a pharmaceutical composition containing the compound, and uses of the compound.Type: ApplicationFiled: January 19, 2012Publication date: August 23, 2012Inventors: Takanao Otsuka, Hirotsugu Ueda, Keiko Fujie, Hideyuki Muramatsu, Michizane Hashimoto, Shigehiro Takase
-
Publication number: 20120213768Abstract: Biomarkers and therapies against autoimmune diseases, including systemic lupus erythematosus (SLE) are described herein. The present invention is based on the discovery of B cell maturation antigen (BCMA) and BCMA variant expression on SLE monocytes that can be directly associated with disease activity. The findings of the present invention enable the design of monoclonal antibodies or recombinant proteins that can block BCMA and BCMA variants as well as BCMA-bound APRIL.Type: ApplicationFiled: February 16, 2012Publication date: August 23, 2012Applicant: BAYLOR RESEARCH INSTITUTEInventors: SangKon Oh, Maria Virginia Pascual, Gerard Zurawski, Jacques F. Banchereau
-
Publication number: 20120208743Abstract: The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).Type: ApplicationFiled: April 25, 2012Publication date: August 16, 2012Inventors: Thomas P. STOSSEL, Teresia Anna Charlotta Magnuson Osborn, Andrej Tarkowski, Erlc Leuchovius
-
Publication number: 20120204276Abstract: The invention relates to methods of regulating complement. In particular, the inventors have identified a relationship between a particular gene, CFHR5, and irregularities in complement regulation. The invention provides a method for diagnosing a complement related disease, comprising identifying a mutation in the CFHR5 gene in a sample obtained from a subject.Type: ApplicationFiled: July 6, 2010Publication date: August 9, 2012Applicant: UCL BUSINESS PLCInventors: Daniel Gale, Patrick Maxwell, Matthew Pickering, Elena Goicoechea De Jorge
-
Publication number: 20120202733Abstract: Peptides are provided consisting of L- and/or D-amino acids and combinations thereof, which affect myeloid cells by action on the triggering receptors expressed on myeloid cells (TREMs), including TREM-1 and TREM-2. The peptides act on the TREM/DAP-12 signaling complex. Also provided are lipid and sugar conjugated peptides comprising L- or D-amino acids. A method is provided of designing the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D-amino acids. The disclosure relates to the therapy of various myeloid cell-related disease states involving the use of these peptides and compounds. The peptides and compounds are useful in the treatment and/or prevention of a disease or condition where myeloid cells are involved or recruited. The peptides of the present invention also are useful in the production of medical devices comprising peptide matrices (for example, medical implants and implantable devices).Type: ApplicationFiled: October 13, 2010Publication date: August 9, 2012Applicant: SIGNABLOK, INC.Inventor: Alexander B. Sigalov
-
Publication number: 20120196790Abstract: The present application relates to cyclic depsipeptides, or derivatives thereof, having the structure of formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7 and human neutrophil elastase.Type: ApplicationFiled: February 14, 2012Publication date: August 2, 2012Applicant: NOVARTIS AGInventors: Philipp KRASTEL, Brigitta-Maria LIECHTY, Josef Gottfried MEINGASSNER, Esther SCHMITT, Erwin Paul SCHREINER
-
Publication number: 20120196789Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: ApplicationFiled: October 5, 2010Publication date: August 2, 2012Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, JR.
-
Patent number: 8232248Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.Type: GrantFiled: July 17, 2009Date of Patent: July 31, 2012Assignee: Novozymes Adenium Biotech A/SInventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
-
Patent number: 8232243Abstract: The invention relates to the use of tryptophan-containing, in particular tryptophan- and tyrosine-containing, peptides as antioxidants. The compounds can be used for the therapy or prophylaxis of syndromes and disorders associated with unwanted oxidative processes in the extracellular space.Type: GrantFiled: December 4, 2000Date of Patent: July 31, 2012Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V.Inventors: Bernd Moosmann, Christian Behl
-
Publication number: 20120190612Abstract: The present invention relates to methods for inhibiting proliferation and/or migration of lymphatic endothelial cells and for inhibiting lymphangiogenesis, comprising administering to a subject, or to lymphatic endothelial cells derived therefrom, an effective amount of a collagen type IV-derived NC1 domain polypeptide or a fragment, derivative or variant thereof, a polynucleotide encoding the same, or an agent capable of increasing the expression or production of the NC1 domain polypeptide. Aso provided are methods for the treatment or prevention of diseases and conditions associated with aberrant lymphatic endothelial cell activity.Type: ApplicationFiled: June 9, 2010Publication date: July 26, 2012Applicant: CRC FOR ASTHMA AND AIRWAYS LTD.Inventors: Judith Lee Black, Janette Kay Burgess, Brian Gregory George Oliver, Markus Weckmann
-
Publication number: 20120189690Abstract: The invention relates to the field of biotechnology and medicine. The invention specifically relates to a compound comprising a liposome covered or decorated at least with the extracellular domain of the APO2L/TRAIL protein, and to the use thereof far developing a medicament preferably for the treatment of a cancer or inflammatory or autoimmune diseases, such as rheumatoid arthritis.Type: ApplicationFiled: August 12, 2010Publication date: July 26, 2012Applicants: Universidad De Zaragoza, Consejo Superior De Investigaciones Cientificas, Universidad Del Pais Vasco/Euskal Herriko UnibertsitateaInventors: Luis Alberto Anel Bernal, Maria Jose Martinez Lorenzo, Luis Martinez Lostao, Maria Angeles Alava Martinez De Contrasta, Luis Larrad Mur, Javier Naval Iraberri, Andres Pineiro Anton, Gorka Basanez Asua
-
Publication number: 20120183524Abstract: Molecular targets and methods for treating inflammatory disorders are described. The expression and/or functionality of molecular targets RelB or SIRT1 is modified in order to treat inflammatory disorders. The expression of RelB or SIRT1 may be increased, or the activity of RelB or SIRT1 may be increased in order to inhibit transcription factors which activate genes involved in inflammation. Inflammatory disorders such as chronic obstructive pulmonary disorder, rheumatoid arthritis, asthma and idiopathic pulmonary fibrosis are indicated.Type: ApplicationFiled: August 8, 2008Publication date: July 19, 2012Applicant: University Of RochesterInventor: Irfan Rahman
-
Publication number: 20120183538Abstract: The invention provides SPARC antisense oligonucleotides and methods of their use in proliferative diseases such as cancer and hepatic fibrosis.Type: ApplicationFiled: July 9, 2010Publication date: July 19, 2012Applicant: ABRAXIS BIOSCIENCE, LLCInventors: Vuong Trieu, Larn Hwang, Neil Desai
-
Publication number: 20120177654Abstract: The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.Type: ApplicationFiled: December 23, 2011Publication date: July 12, 2012Applicant: THE UNIVERSITY OF MELBOURNEInventors: John Hamilton, Gary Peter Anderson, Ian Keith Campbell
-
Publication number: 20120178669Abstract: This invention relates to grassystatins A, B and C, and their isolated or purified forms. The compounds of the invention are useful as aspartic protease, gamma secretase, or metalloprotease inhibitors. Methods of using the compounds and compositions thereof are also disclosed.Type: ApplicationFiled: June 26, 2010Publication date: July 12, 2012Applicant: University of Florida Research Foundation, Inc.Inventors: Hendrik Luesch, Valerie J. Paul, Jason C. Kwan
-
Publication number: 20120171221Abstract: Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a sample of tear from the mammal with an antibody that specifically binds to a first polypeptide selected from the group Ctss, Ctsh, Ctsr, Ctsw, Ctsz, Ifng, Il16ra, Il10, Il10ra, Il15, Tnfa, Apo-F, or Lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided.Type: ApplicationFiled: July 6, 2010Publication date: July 5, 2012Inventors: Sarah Hamm-Alvarez, Kaijin Wu, Maria Charlotta Edman
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Publication number: 20120172297Abstract: Synthetic human target autoantigen genes comprising sequences coding for at least two immunogenic epitopic clusters (hereinafter IEC) of autoantigen(s) related to a specific autoimmune disease, wherein said at least two IECs may be derived from a sole autoantigen or from at least two different autoantigens related to said autoimmune disease, and polypeptides encoded thereby, can be used for the treatment and the diagnosis of autoimmune diseases such as multiple sclerosis (MS), insulin-dependent diabetes mellitus (IDDM), rheumatoid arthritis (RA), myasthenia gravis (MG) and uveitis.Type: ApplicationFiled: December 29, 2011Publication date: July 5, 2012Inventors: AVRAHAM BEN-NUN, NICOLE KERLERO DE ROSBO, PAUL GREGOR SAPPLER
-
Publication number: 20120148498Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.Type: ApplicationFiled: February 28, 2012Publication date: June 14, 2012Applicant: Baylor Research InstituteInventors: Jacques Banchereau, Virginia Pascual
-
Publication number: 20120142585Abstract: This invention provides compounds that are true antagonists of the leptin receptor, in the presence and the absence of native leptin or another leptin receptor binder. These compounds may be used to inhibit leptin receptor activity, promote growth arrest or death of leptin receptor-positive cancer cells, or monitor or detect a leptin receptor-positive cell, in vitro or in vivo. These compounds may also be used to treat a weight-loss nutritional disorder, osteoporosis, rheumatoid arthritis, osteoarthritis, or inflammatory bowel disease. Also included in the invention are methods for detecting leptin receptor-positive cells, for arresting cell growth or killing cancer cells in vivo, for monitoring or detecting a leptin receptor-positive cell in vitro or in vivo, for treating a weight-loss nutritional disorder, for treating osteoporosis, for treating rheumatoid arthritis, for treating osteoarthritis, or for treating inflammatory bowel disease.Type: ApplicationFiled: March 30, 2010Publication date: June 7, 2012Applicant: TEMPLE UNIVERSITY-OF THE C0MMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laszlo Otvos, Eva Surmacz
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Publication number: 20120141505Abstract: Provided herein are CD19-ligand (CD19-L) polypeptides and polynucleotides encoding such CD19-L polypeptides. Methods related to diagnosing and treating a disorder associated with CD19 positive B-cells in a patient using a CD19-L polypeptide are also provided.Type: ApplicationFiled: October 31, 2011Publication date: June 7, 2012Inventor: Fatih M. Uckun
-
Publication number: 20120134997Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: September 3, 2008Publication date: May 31, 2012Applicant: COMPUGEN LTD.Inventors: Zurit Levine, Tania Pergam, Dalit Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Oler Levy, Marina Bubis
-
Publication number: 20120135916Abstract: Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.Type: ApplicationFiled: April 13, 2010Publication date: May 31, 2012Applicant: Siemens Healthcare Diagnostics Inc.Inventors: Michael J. Pugia, Rui Ma
-
Publication number: 20120129779Abstract: The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases.Type: ApplicationFiled: May 9, 2008Publication date: May 24, 2012Applicant: R&D-BIOPHARMACEUTICALS GMBHInventor: Wolfgang Richter
-
Publication number: 20120129778Abstract: The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. The disclosure also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signaling and a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis.Type: ApplicationFiled: July 27, 2010Publication date: May 24, 2012Applicant: Glaxo Group LimitedInventors: Caroline J. Dimech, Adriaan Allart Stoop, Rudolf Maria De Wildt, Steve Holmes
-
Patent number: 8183201Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.Type: GrantFiled: February 25, 2011Date of Patent: May 22, 2012Assignees: National Cheng Kung University, National Taiwan UniversityInventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang